CLDN18.2 CAR-T cells + PD-L1 CAR-T cells

This therapy is a combination of two chimeric antigen receptor T cell (CAR-T) products—one targeting Claudin 18.2 (CLDN18.2), a tight junction protein highly expressed in several solid tumors such as gastric and pancreatic cancers, and the other targeting programmed death-ligand 1 (PD-L1), an immune checkpoint molecule often upregulated in the tumor microenvironment[4][8]. The rationale for this combination is to simultaneously target tumor-specific antigens (CLDN18.2) while overcoming immunosuppression mediated by the PD-1/PD-L1 axis, which can limit the efficacy of single-agent therapies[4][6][9]. Dual-targeting approaches are designed to enhance anti-tumor activity by both direct cytotoxicity against cancer cells expressing these markers and modulation of the immunosuppressive tumor microenvironment[4][8]. This strategy is under clinical investigation for patients with advanced solid tumors that express CLDN18.2, particularly those who have not responded to standard treatments such as chemotherapy or immune checkpoint inhibitors[4].

Other names

CLDN18.2/PD-L1 dual-targeting CAR-Tdual-targeting CLDN18.2 and PD-L1 CAR-T